P. Kenemans

C. Stehouwer, P. Kenemans, J. C. Netelenbos, 1999, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Therapeutic options for postmenopausal female sexual

P. Kenemans, J. Studd, R. Nappi, 2009 .

Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy.

P. Kenemans, A. Mueck, J. Bitzer, 2008, Maturitas.

Pulsed estrogen exposure selectively modulates tissue response: a hypothesis

P. Kenemans, A. Genazzani, H. Schneider, 2004, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study.

C. Stehouwer, P. Kenemans, C. Netelenbos, 1999, Arteriosclerosis, thrombosis, and vascular biology.

Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia

J. Walboomers, P. Kenemans, C. Meijer, 1991, International journal of cancer.

Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial.

M. Beckmann, J. Foidart, P. Sismondi, 2007, Breast.

The Million Women Study: a licence to kill other investigations?

P. Kenemans, M. J. van der Mooren, 2004, European journal of obstetrics, gynecology, and reproductive biology.

Cancer Risk Associated with Subfertility and Ovulation Induction: A Review

F. V. van Leeuwen, P. Kenemans, H. Klip, 2000, Cancer Causes & Control.

Breast cancer and post-menopausal hormone therapy.

P. Kenemans, A. Bosman, 2003, Best practice & research. Clinical endocrinology & metabolism.

Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies.

O. Kamp, P. Kenemans, T. Vogelvang, 2002, American journal of obstetrics and gynecology.

A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine.

W. M. van Baal, P. Kenemans, T. Vogelvang, 2002, Maturitas.

Perspectives in hormone replacement therapy.

P. Kenemans, V. Mijatovic, M. J. van der Mooren, 2001, Maturitas.

Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study.

W. M. van Baal, P. Kenemans, J. C. Netelenbos, 2001, American journal of obstetrics and gynecology.

Continuation rates for oral contraceptives and hormone replacement therapy. The ESHRE Capri Workshop Group.

P. Crosignani, E. Diczfalusy, B. Tarlatzis, 2000, Human reproduction.

Postmenopausal sex hormones and cancer of the endometrium and breast

P. Kenemans, G. V. van Unnik, 2000 .

Hormonal prevention of breast cancer: proposal for a change in paradigm

P. Kenemans, R. Hesch, 1999, British journal of obstetrics and gynaecology.

Postmenopausal hormone replacement in the woman with a reproductive risk factor for breast cancer.

P. Kenemans, C. Burger, F. Scheele, 1999, Maturitas.

Hormone replacement therapy in women treated for gynaecological malignancy.

F. V. van Leeuwen, P. Kenemans, C. Burger, 1999, Maturitas.

Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.

P. Kenemans, C. Netelenbos, C. Jakobs, 1998, Fertility and sterility.

Detection of Genital Human Papilloma Virus Infections by the Polymerase Chain Reaction

J. Walboomers, P. Kenemans, P. Snijders, 1991 .

Accumulation of p 53 protein is frequent in ovarian cancers associated with BRCA 1 and BRCA 2 germline mutations

I. Jacobs, B. Ponder, A. Berchuck, 1999 .

SEM technology, parameters and interpretations

P. Kenemans, E. Hafez, 1982 .

Specimen preparation techniques

V. P. Collins, P. Kenemans, U. Brunk, 1982 .

Hormone Replacement Therapy after Breast Cancer

P. Kenemans, F. Scheele, 1997 .

Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women

C. Stehouwer, C. Schalkwijk, W. M. van Baal, 2005, Menopause.

Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial

C. Hack, P. Kenemans, C. Klipping, 2008, Menopause.

Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review.

P. Kenemans, C. Kluft, M. J. van der Mooren, 2008, Fertility and sterility.

Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women

P. Kenemans, T. Vogelvang, T. Teerlink, 2007, Menopause.

Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women.

P. Kenemans, M. J. van der Mooren, M. Hemelaar, 2006, Fertility and sterility.

Different effects of low-dose transdermal and oral oestrogen therapy on procarboxypeptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: A randomised, placebo-controlled study

C. Stehouwer, W. M. van Baal, P. Kenemans, 2005, Thrombosis and Haemostasis.

The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.

P. Kenemans, T. Vogelvang, V. Mijatovic, 2005, American journal of obstetrics and gynecology.

Endothelium-dependent dilatory effects of 3α-OH-tibolone in gracilis muscle arterioles of the female Wistar rat

P. Sipkema, P. Kenemans, H. Kloosterboer, 2005, Menopause.

HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women.

P. Kenemans, T. Vogelvang, T. Teerlink, 2004, Fertility and sterility.

Observer agreement on interpreting colposcopic images of CIN.

P. Kenemans, F. Voorhorst, T. Helmerhorst, 1995, Gynecologic oncology.

The Prognostic and Clinical Value of Morphometry and DNA Cytometry in Borderline Ovarian Tumors: A Prospective Study

P. V. van Diest, J. Baak, P. Kenemans, 2009, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a).

P. Kenemans, M. J. van der Mooren, R. Smolders, 2004, Maturitas.

Histopathologic Features of Genetically Determined Ovarian Cancer

I. Jacobs, A. Ryan, H. Risch, 2002, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study

P. V. van Diest, P. Kenemans, R. Verheijen, 2004, Familial Cancer.

Comparative Immunohistochemical Study of Four Monoclonal Antibodies Directed Against Ovarian Carcinoma‐Associated Antigens

P. Kenemans, O. Boerman, L. Poels, 1991, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study

P. Kenemans, R. Verheijen, H. M. Prinssen, 1997, Cancer.

Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study

P. Kenemans, R. Verstraeten, R. Verheijen, 2002, Journal of Cancer Research and Clinical Oncology.

Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer.

M. A. Plaizier, P. Kenemans, R. Verheijen, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Increased resistance to activated protein C after short‐term oral hormone replacement therapy in healthy post‐menopausal women

C. Stehouwer, W. M. van Baal, P. Kenemans, 2002, British journal of haematology.

Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study

P. Kenemans, P. Verdegem, M. J. van der Mooren, 2005, Menopause.

Breast cancer and climacteric complaints: weighing up risks of hormone therapy against quality of life.

P. Kenemans, C. Burger, M. J. van der Mooren, 2007, European journal of obstetrics, gynecology, and reproductive biology.

Less mammographic density after nasal versus oral administration of postmenopausal hormone therapy

N. Karssemeijer, J. Otten, A. Verbeek, 2011, Climacteric : the journal of the International Menopause Society.

Women's health after WHI.

P. Kenemans, 2005, Maturitas.

Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.

P. Kenemans, L. Speroff, Peter Kenemans, 2005, Maturitas.

Sex hormones, anti-hormones and adenocarcinoma of the endometrium

P. Kenemans, R. Verstraeten, 2005 .

High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy

J. Walboomers, P. Kenemans, L. Rozendaal, 2000, BJOG : an international journal of obstetrics and gynaecology.

Postmenopausal Hormone Use and Endometrial Cancer: Reassessment of the Epidemiological Data

P. Kenemans, C. Burger, G. A. Unnik, 2002 .

CA 125: fundamental and clinical aspects.

P. Kenemans, R. Verheijen, G. V. van Kamp, 1999, Seminars in cancer biology.

Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal antibody fragments in patients with ovarian cancer.

P. Kenemans, L. Massuger, W. Buijs, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Dosimetric Evaluationof Immunoscintigraphy Using Indium-i 11-LabeledMonoclonal Antibody Fragmentsin Patientswith OvarianCancer

P. Kenemans, F. Corstens, 1992 .

Endometrial Effects of Tibolone in Elderly, Osteoporotic Women

Susan R. Johnson, S. Cummings, B. Ettinger, 2008, Obstetrics and gynecology.

Evaluation of the Serum Markers CA 125, CA 15.3 and CA M29 in Monitoring Ovarian Cancer

P. Kenemans, J. Vermorken, L. Rozendaal, 1993 .

Comparison of seven immunoassays for the quantification of CA 125 antigen in serum.

P. Kenemans, R. Verstraeten, G. V. van Kamp, 1998, Clinical chemistry.

Technical evaluation of three second generation CA 125 assays.

P. Kenemans, J. Bonfrer, A. Baan, 1994, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer.

P. V. van Diest, C. Meijer, P. Kenemans, 2001, European journal of obstetrics, gynecology, and reproductive biology.

Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.

B. Ponder, A. Berchuck, I. Jacobs, 1999, Journal of clinical pathology.

Comparative Genomic Hybridization of Microdissected Familial Ovarian Carcinoma: Two Deleted Regions on Chromosome 15q Not Previously Identified in Sporadic Ovarian Carcinoma

A. Snijders, I. Jacobs, A. Ryan, 2001, Laboratory Investigation.

Tumor uptake of intravenously administered radiolabeled antibodies in ovarian carcinoma patients in relation to antigen expression and other tumor characteristics

J. Baak, P. Kenemans, M. Brinkhuis, 1995, International journal of cancer.

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53

S. H. van der Burg, J. Drijfhout, W. Kast, 1993, European journal of immunology.

A Combination of Serum Tumor Markers Identifies High-Risk Patients with Early-Stage Squamous Cervical Cancer

M. Blankenstein, P. Kenemans, R. Verheijen, 2008, Tumor Biology.

Hormone replacement therapy in patients at high risk of developing breast cancer: The use of a combined risk model

P. Kenemans, F. Scheele, 1997 .

Androgens and breast cancer risk

P. Kenemans, M. J. van der Mooren, 2012, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Micturition complaints in postmenopausal women treated with continuously combined hormone replacement therapy: a prospective study.

P. Kenemans, C. Burger, G. Voetberg, 1999, Maturitas.

Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.

P. Sismondi, N. Biglia, R. Kimmig, 2011, Maturitas.

Tibolone: how does its mechanism of action translate into clinical effects.

P. Kenemans, 2004, Maturitas.

Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy

M. Beckmann, J. Foidart, P. Sismondi, 2012, Breast Cancer Research.

Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism.

P. Kenemans, J. C. Netelenbos, G. Voetberg, 1994, The Journal of clinical endocrinology and metabolism.

Urinary and faecal incontinence in community-residing elderly women.

P. Kenemans, C. Burger, F. Voorhorst, 1992, Age and ageing.

Clinical Relevance of the Tumor Marker CA 15.3 in the Management of Cancer Patients

P. Kenemans, H. Nijman, G. Kamp, 1990 .

Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose.

A. Perkins, P. Kenemans, R. Verheijen, 1996, Cancer research.

Objective Biomarkers in Endometrioid-Type Endometrial Carcinogenesis

P. Diest, J. Baak, P. Kenemans, 2005 .

Postmenopausal Hormone Replacement Therapy and Gynecological Malignancies

P. Kenemans, C. Burger, F. Scheele, 1999 .

Hormone replacement therapy and breast cancer morbidity, mortality and recurrence.

P. Kenemans, C. Burger, F. Scheele, 1997, European journal of obstetrics, gynecology, and reproductive biology.

Hormone replacement therapy and breast cancer.

M. Stampfer, P. Kenemans, P. Kenemans, 1996, European journal of obstetrics, gynecology, and reproductive biology.

Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n‐acetylgalactosamine (GalNAc) peptides

M. Price, P. Kenemans, Philip S. Livingston, 2000, International journal of cancer.

Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition

P. V. van Diest, G. Pals, P. Kenemans, 2003, Histopathology.

Human MUC1 Mucin: A Multifaceted Glycoprotein

P. Kenemans, A. Verstraeten, S. von Mensdorff‐Pouilly, 2000, The International journal of biological markers.

Antibody‐dependent cell‐mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients

P. Kenemans, Philip S. Livingston, A. Verstraeten, 2001, International journal of cancer.

Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study.

M. Blankenstein, C. Stehouwer, W. M. van Baal, 2003, American journal of obstetrics and gynecology.

The second generation CA 125 assays.

P. Kenemans, G. V. van Kamp, A. Verstraeten, 1995, Annals of medicine.

Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.

J. Berkhof, P. V. van Diest, M. Blankenstein, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo‐ controlled, 12‐week study in early postmenopausal women

C. Stehouwer, W. M. van Baal, P. Kenemans, 2002, Journal of internal medicine.

Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women.

C. Stehouwer, C. Schalkwijk, W. M. van Baal, 1999, Fertility and sterility.

CA 125 in gynecological pathology--a review.

P. Kenemans, G. Bon, S. von Mensdorff‐Pouilly, 1993, European journal of obstetrics, gynecology, and reproductive biology.

An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma

A. Perkins, P. Kenemans, R. Verheijen, 1999, British journal of obstetrics and gynaecology.

Tannic acid binding of cell surfaces in normal, premalignant, and malignant squamous epithelium of the human uterine cervix.

G. Lamers, P. Kenemans, U. Van Haelst, 1984, Ultrastructural pathology.

Clinical applications of monoclonal antibodies against ovarian cancer-associated antigens.

P. Kenemans, R. Verheijen, L. Massuger, 1988, European journal of obstetrics, gynecology, and reproductive biology.

Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen.

P. Kenemans, C. Molthoff, M. Buist, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients.

J. Baak, P. Kenemans, C. Burger, 1993, Cancer research.

Differences inMHC andTAP-1expression incervical cancerlymphnode metastases ascompared withtheprimary tumours

C. Meijer, J. Walboomers, P. Stern, 1994 .

Impaired Procoagulant-anticoagulant Balance during Hormone Replacement Therapy?

C. Stehouwer, W. M. van Baal, P. Kenemans, 2000, Thrombosis and Haemostasis.

Postmenopausal oestradiol-dydrogesterone therapy favourably affects fibrinolysis and Lp(a) in healthy women

M. Moore, C. Stehouwer, P. Kenemans, 1999 .

Discordant serum CA 125 values in commercial immunoassays.

P. Kenemans, G. V. van Kamp, A. Verstraeten, 1993, European journal of obstetrics, gynecology, and reproductive biology.

Monoclonal antibodies that discriminate between human ovarian carcinomas and benign ovarian tumours.

A. Hanselaar, P. Kenemans, O. Boerman, 1990, European journal of cancer.

CA 125 and OA 3 as target antigens for immunodiagnosis and immunotherapy in ovarian cancer.

P. Kenemans, 1990, European journal of obstetrics, gynecology, and reproductive biology.

Biodistribution, Binding and Internalisation of Monoclonal Antibodies to Human Ovarian Carcinoma Cells

P. Jap, P. Kenemans, L. Massuger, 1990 .

Prospects and applications of monoclonal antibodies in gynecological oncology.

P. Kenemans, R. Verheijen, L. Poels, 1985, European journal of obstetrics, gynecology, and reproductive biology.

Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours.

S. Meijer, P. Kenemans, J. Vermorken, 1996, European journal of cancer.

Quantitation of polymorphic epithelial mucin: a challenge for biochemists and immunologists.

P. Kenemans, A. Verstraeten, J. Hilgers, 1995, Scandinavian journal of clinical and laboratory investigation. Supplementum.

Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study

P. Kenemans, V. Mijatovic, M. J. van der Mooren, 2003, Menopause.

Characterization of a New MUC1 Monoclonal Antibody (VU-2-G7) Directed to the Glycosylated PDTR Sequence of MUC1

P. Kenemans, R. Verstraeten, J. Hilgers, 2000, Tumor Biology.

Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause.

P. Kenemans, R. Verheijen, J. Piek, 2004, American journal of obstetrics and gynecology.

CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery.

T. Wobbes, P. Kenemans, R. Verstraeten, 1993, European journal of cancer.

Immunoscintigraphyof OvarianCancerwith Indium-i 11-LabeledOV-TL 3 F(ab')2 Monoclonal Antibody

P. Kenemans, S. Strijk, Lambert G. Pods, 1990 .

17 beta-Estradiol induces a rapid, endothelium-dependent, sex-specific vasodilatation in spontaneous constricted rat arterioles.

P. Sipkema, C. Stehouwer, P. Kenemans, 2002, American journal of obstetrics and gynecology.

A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels.

C. Stehouwer, P. Kenemans, T. Teerlink, 2003, Fertility and sterility.

Hormone replacement therapy and plasma homocysteine levels.

W. M. van Baal, P. Kenemans, T. Teerlink, 1999, Obstetrics and gynecology.

Oral 17β-Estradiol Continuously Combined with Dydrogesterone Lowers Serum Lipoprotein(a) Concentrations in Healthy Postmenopausal Women1

P. Kenemans, J. C. Netelenbos, G. Kamp, 1997 .

Homocysteine impairs estrogen-induced vasodilation in isolated rat arterioles

P. Sipkema, C. Stehouwer, P. Kenemans, 2004, Menopause.

Quality of life in breast cancer patients

P. Kenemans, 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

‘Epitope Fingerprinting’ Using Overlapping 20-mer Peptides of the MUC1 Tandem Repeat Sequence

P. Kenemans, R. Verstraeten, J. Hilgers, 1997, Tumor Biology.

Foscan‐mediated photodynamic therapy for a peritoneal‐cancer model: Drug distribution and efficacy studies

H. Oppelaar, M. Ruevekamp, R. Veenhuizen, 1997, International journal of cancer.

Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations.

P. V. van Diest, I. Jacobs, A. Ryan, 2000, Gynecologic oncology.

Feasibility of a concanavalin A-peroxidase labeling method to detect cancerous and precancerous lesions of the uterine cervix.

P. Kenemans, U. Van Haelst, A. Stadhouders, 1986, Cancer research.

Effects of 15 months of 17 beta-estradiol and dydrogesterone on systolic cardiac function according to quantitative and Doppler echocardiography in healthy postmenopausal women.

C. Visser, O. Kamp, W. M. van Baal, 2001, American journal of obstetrics and gynecology.

Ambulatory--not office--blood pressures decline during hormone replacement therapy in healthy postmenopausal women.

F. V. van Ittersum, A. Donker, C. Stehouwer, 1998, American journal of hypertension.

A Randomized Controlled Study of the Effects of 17Beta‐Estradiol‐Dydrogesterone on Plasma Homocysteine in Postmenopausal Women

W. M. van Baal, P. Kenemans, C. Jakobs, 1998, Obstetrics and gynecology.

Postmenopausal hormone replacement therapy in the light of the women's health initiative trial.

P. Kenemans, M. J. van der Mooren, 2003, European journal of obstetrics, gynecology, and reproductive biology.

Effects of hormone replacement therapy on blood platelets

C. Stehouwer, W. M. van Baal, P. Kenemans, 2002, European journal of clinical investigation.

Less Effect of Intranasal Than Oral Hormone Therapy on Factors Associated With Venous Thrombosis Risk in Healthy Postmenopausal Women

P. Kenemans, J. Rosing, D. Braat, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells

W. Kast, C. Melief, H. Geuze, 1995, The Journal of experimental medicine.

Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms.

C. Christiansen, O. Chevallier, P. Kenemans, 2000, American journal of obstetrics and gynecology.

Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer.

C. Meijer, P. Kenemans, R. Verstraeten, 1999, European journal of obstetrics, gynecology, and reproductive biology.

Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy.

P. Kenemans, M. de Vries, P. V. D. van de Weijer, 1999, Obstetrics and gynecology.

Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions.

C. Meijer, J. Walboomers, P. Stern, 1993, British Journal of Cancer.

Effects of Transdermal and Oral Oestrogen Replacement Therapy on C-Reactive Protein Levels in Postmenopausal Women: A Randomised, Placebo-Controlled Trial

C. Stehouwer, C. Schalkwijk, W. M. van Baal, 2002, Thrombosis and Haemostasis.

Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes.

J. Drijfhout, W. Kast, P. Kenemans, 1997, Cancer letters.

The cellular composition in the peritoneal cavity and the cytotoxic function of the peritoneal cells from patients with ovarian cancer; effect of tumor necrosis factor-alpha treatment.

P. Kenemans, C. Burger, A. A. van de Loosdrecht, 1993, Cancer letters.

Confirmation of the prognostic value of the ECPI-1 score (myometrial invasion, DNA-ploidy and mean shortest nuclear axis) in FIGO stage I endometrial cancer patients with long follow-up

P. V. van Diest, P. Kenemans, J. Baak, 1994, International Journal of Gynecologic Cancer.

Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.

T. Wobbes, P. Kenemans, F. Voorhorst, 1992, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Ultrasound assessment of the endometrium in healthy, asymptomatic early post‐menopausal women: saline infusion sonohysterography versus transvaginal ultrasound

P. Kenemans, M. J. van der Mooren, H. Kessel, 2000, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract

J. Baak, P. Kenemans, C. Burger, 1993, International Journal of Gynecologic Cancer.

P. V. van Diest, P. Kenemans, R. Verheijen, 2003, Gynecologic oncology.

Laparoscopic detection of sentinel lymph nodes followed by lymph node dissection in patients with early stage cervical cancer.

P. V. van Diest, P. Kenemans, A. van Lingen, 2003, Gynecologic oncology.

Applications of a human tumour clonogenic cell culture system in gynaecological oncology: review and personal experience.

P. Kenemans, R. Verheijen, C. Herman, 1984, European journal of obstetrics, gynecology, and reproductive biology.

Time course of ovarian tumour growth in soft agar culture.

G. P. Vooys, P. Kenemans, R. Verheijen, 1985, British Journal of Cancer.

Timecourseofovarian tumourgrowth insoft agarculture

G. P. Vooys, P. Kenemans, R. Verheijen, 1985 .

Expression of Multidrug Resistance-Associated Markers, Their Relation to Quantitative Pathologic Tumour Characteristics and Prognosis in Advanced Ovarian Cancer

P. V. van Diest, J. Baak, P. Kenemans, 2002, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases.

J. Baak, P. Kenemans, C. Burger, 1992, European journal of cancer.

LIBERATE trial: A safety study of tibolone in breast cancer surgery patients

M. Beckmann, P. Sismondi, R. Kimmig, 2006 .

Evaluation of colorectal cancer-associated mucin CA M43 assay in serum.

A. Kok, T. Wobbes, J. Brown, 1993, Clinical chemistry.

LHRH agonist treatment of breast cancer and gynecological malignancies: a review.

P. Kenemans, C. Burger, H. M. Prinssen, 1996, European journal of obstetrics, gynecology, and reproductive biology.

Quantification of MUC1 in breast cancer patients. A method comparison study.

P. Kenemans, R. Verstraeten, G. V. van Kamp, 1999, European journal of obstetrics, gynecology, and reproductive biology.

Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels.

P. Kenemans, C. Netelenbos, C. Popp‐Snijders, 1998, Fertility and sterility.

Monoclonal antibody against human ovarian tumor-associated antigens.

P. Jap, P. Kenemans, Y. V. van Megen, 1986, Journal of the National Cancer Institute.

Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women.

C. Stehouwer, P. Kenemans, T. Teerlink, 2003, The Journal of clinical endocrinology and metabolism.

Tubal ligation and risk of ovarian cancer

P. Diest, P. Kenemans, R. Verheijen, 2001, The Lancet.

Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.

P. Kenemans, C. Netelenbos, V. Mijatovic, 1999, Menopause.

Hormone replacement therapy: a useful tool in the prevention of coronary artery disease in postmenopausal women?

K. Meeter, P. Kenemans, C. Kluft, 1996 .

Intranasal horm one therapy Part II Intranasal hormone therapy

P. Kenemans, P. Weijer, M. J. Mooren, 2007 .

SENTINEL NODE DETECTION IN CERVICAL CANCER

P. V. van Diest, P. Kenemans, R. Verheijen, 2000, Obstetrics and gynecology.

Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women

P. Kenemans, T. Vogelvang, J. C. Netelenbos, 2004, Menopause.

Effects of oral and transdermal low-dose estrogen therapy on echocardiographic parameters of cardiac function.

C. Visser, O. Kamp, P. Kenemans, 2003, Fertility and sterility.

Concanavalin A-peroxidase labeling in cervical exfoliative cytopathology. I. Labeling of normal squamous cells and the detection of cancer.

G. Lamers, P. Kenemans, U. Van Haelst, 1985, Gynecologic oncology.

Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover.

P. Kenemans, J. C. Netelenbos, C. Popp‐Snijders, 1997, Maturitas.

Efficacy of a synthetic mesh sling in keeping the small bowel in the upper abdomen to prevent radiation enteropathy in gynecologic malignancies.

P. Kenemans, C. Burger, T. Helmerhorst, 1993, European journal of obstetrics, gynecology, and reproductive biology.

Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab′)2: pharmacokinetics, tissue distribution, and tumor imaging

R. Golding, J. Baak, G. Teule, 1991, International Journal of Gynecologic Cancer.

Multiple parameter analyses of human ovarian cancer: morphology, immunohistochemistry, steroid hormone receptors and aromatase.

P. Kenemans, J. Delemarre, J. Stolk, 1988, Anticancer Research.

High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC).

P. Kenemans, H. Bontkes, R. Scheper, 2007, Cancer letters.

Expression of cytokeratin 10, 13, and involucrin as prognostic factors in low stage squamous cell carcinoma of the uterine cervix

M. Gallee, P. Kenemans, D. Iványi, 1994, Cancer.

Experimental and Clinical Analysis of the Characteristics of a Chimeric Monoclonal Antibody, M0v18, Reactive with an Ovarian Cancer-AssociatedAntigen

P. Kenemans, C. Molthoff, M. Buist, 1992 .

Cell DNA content — Correlation with clonogenicity in the human tumour cloning system (HTCS)

G. P. Vooys, F. Debruyne, P. Kenemans, 1985, International journal of cancer.

In-use evaluation of the Omnicon automated tumor colony counter.

F. Debruyne, P. Kenemans, R. Verheijen, 1983, Cytometry.

Sequentially combined hormone replacement therapy reduces impedance to flow within the uterine and central retinal arteries in healthy postmenopausal women.

C. Stehouwer, P. Kenemans, J. V. van Vugt, 1999, American journal of obstetrics and gynecology.

Distribution ofOV-TL3andMOv18innormal andmalignant ovarian tissue

C. Meijer, P. Kenemans, M. Buist, 2011 .

Endocervical curettage by Vabra aspiration as part of colposcopic evaluation.

E. Risse, P. Kenemans, J. Stolk, 1990, Gynecologic oncology.

Prognostic factors in borderline and invasive ovarian tumors of the common epithelial type.

J. Baak, P. Kenemans, J. Stolk, 1987, Pathology, Research and Practice.

Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma.

R. Veenhuizen, F. Stewart, P. Kenemans, 1996, British Journal of Cancer.

Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01

A. Perkins, P. Kenemans, R. Verheijen, 1998, Cancer Immunology, Immunotherapy.

P. V. van Diest, P. Kenemans, R. Verheijen, 2001, Histopathology.

Digital color imaging colposcopy: a matter of choice.

P. Kenemans, R. Verheijen, L. Rozendaal, 1998, European journal of obstetrics, gynecology, and reproductive biology.

Atlas of Human Reproduction

P. Kenemans, E. Hafez, 1982, Springer Netherlands.

The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy. A review of the literature.

J J Visser, J. J. Visser, P. Kenemans, 1992, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

XIXth Meeting of the International Society for Oncodevelopment Biology and Medicine, Siena, October 13–17, 1991 (Part 1 of 4)

R. Nicholson, G. Kéri, T. Wobbes, 1992 .

CO2-laser therapy in patients with vulvar intraepithelial neoplasia.

P. Kenemans, J. Stolk, C. H. van der Vaart, 1990, European journal of obstetrics, gynecology, and reproductive biology.

The presence of persistent high‐risk hpv genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months

C. Meijer, J. Walboomers, E. Risse, 1995, International journal of cancer.

Diathermy loop excision in the management of cervical intraepithelial neoplasia: diagnosis and treatment in one procedure.

G. Vooijs, P. Kenemans, R. Rolland, 1992, American journal of obstetrics and gynecology.

Identification of patients with persistent trophoblastic disease by means of a normal human chorionic gonadotropin regression curve.

G. Borm, P. Kenemans, R. Verheijen, 1993, American journal of obstetrics and gynecology.

SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer.

J. Berkhof, P. Kenemans, R. Verheijen, 2009, Gynecologic oncology.

Maternal Serum CA125 and CA15-3 Antigen Levels in Normal and Pathological Pregnancy

H. V. van Geijn, P. Kenemans, J. V. van Vugt, 2001, Fetal Diagnosis and Therapy.

The effects of tibolone in older postmenopausal women.

S. Cummings, C. Christiansen, R. Eastell, 2008, The New England journal of medicine.

Gestational trophoblastic disease: management, the European way.

P. Kenemans, 1994, European journal of obstetrics, gynecology, and reproductive biology.

Epidemiologic Features of Hydatidiform Mole in the Netherlands

G. Vooijs, E. Risse, P. Kenemans, 1983, Obstetrics and gynecology.

Plasma Human Chorionic Gonadotropin Disappearance in Hydatidiform Mole: A Central Registry Report From the Netherlands

G. Vooijs, E. Risse, P. Kenemans, 1983, Obstetrics and gynecology.

The Diagnosis and Management of Partial and Complete Hydatidiform Moles

P. Kenemans, J. Stolk, H. R. Franke, 1986 .

Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study.

C. Sohn, R. Kreienberg, C. Sohn, 1998, Gynecologic oncology.

Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study

R. Kreienberg, C. Sohn, P. Kenemans, 1994, Cancer.

Use of intermediate filament antibodies in the differential diagnosis of gynecological neoplasia.

G. Vooijs, P. Kenemans, F. Ramaekers, 1985, European journal of obstetrics, gynecology, and reproductive biology.

Surface Ultrastructure of the Uterine Cervix and Early Detection of Irreversible Neoplasia

G. P. Vooys, P. Kenemans, A. Stadhouders, 1982 .

Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

P. V. van Diest, A. Kok, S. Meijer, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human papillomavirus DNA and genotypes: prognostic factors for progression of cervical intraepithelial neoplasia

J. Walboomers, P. Kenemans, K. Gaarenstroom, 1993, International Journal of Gynecologic Cancer.

Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer

P. V. van Diest, G. Pals, A. Jongsma, 2001, The Journal of pathology.

Reprint of Oncogenic pathways in hereditary and sporadic breast cancer

P. Kenemans, R. Verstraeten, R. Verheijen, 2008 .

Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study

C. Meijer, J. Walboomers, E. Risse, 1999, The Lancet.

PCR‐based high‐risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears

C. Meijer, J. Walboomers, M. van Ballegooijen, 1996, International journal of cancer.

Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction

C. Meijer, J. Walboomers, P. Kenemans, 1990, Journal of clinical microbiology.

Prevalence ofChlamydia trachomatis infection in a population of asymptomatic women in a screening program for cervical cancer

W. Quint, E. Risse, P. Kenemans, 1989, European Journal of Clinical Microbiology and Infectious Diseases.

Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.

P. V. van Diest, M. Blankenstein, S. Meijer, 2007, European journal of cancer.

Survival analysis in familial ovarian cancer, a case control study.

P. V. van Diest, I. Jacobs, P. Kenemans, 2001, European journal of obstetrics, gynecology, and reproductive biology.

Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays

P. Kenemans, R. Verstraeten, G. V. van Kamp, 2003, Annals of clinical biochemistry.

BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation

A. Shvarts, J. Dorsman, P. Kenemans, 2006, Archives of Gynecology and Obstetrics.

Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer

J. Berkhof, P. V. van Diest, S. Meijer, 2006, International journal of cancer.

Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.

G. Giaccone, A. V. D. Van Der Zee, M. Flens, 1995, Journal of the National Cancer Institute.

Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature.

P. Kenemans, P Kenemans, T J Helmerhorst, 1998, Obstetrical & gynecological survey.

Prospective Multicenter Evaluation of the Morphometric D-Score for Prediction of the Outcome of Endometrial Hyperplasias

P. V. van Diest, J. Baak, P. Kenemans, 2001, The American journal of surgical pathology.

Successful treatment with methotrexate of five vital interstitial pregnancies.

P. Kenemans, F. van der Veen, R. Schats, 1992, Human reproduction.

Clinical evaluation of the Byk LIA-mat CA125 II assay: discussion of a reference value.

P. Kenemans, R. Verstraeten, P Kenemans, 1997, Clinical chemistry.

The management of borderline epithelial tumors of the ovary.

J. Baak, P. Kenemans, C. Burger, 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients.

P. Kenemans, S. Litvinov, G. V. van Kamp, 1995, British Journal of Cancer.

The vagina (normal)

P. Kenemans, E. Hafez, 1982 .

Clinical application of SEM to human reproduction

P. Kenemans, T. Eskes, E. Hafez, 1982 .

The sentinel node in cervical cancer: scintigraphy and laparoscopic gamma probe-guided biopsy

Paul J. van Diest, P. Diest, G. Teule, 2004, European Journal of Nuclear Medicine and Molecular Imaging.

Women’s Health and Menopause

P. Crosignani, P. Kenemans, R. Paoletti, 1997, Medical Science Symposia Series.

Therapeutic options for postmenopausal female sexual dysfunction

C. Castelo-Branco, P. Kenemans, J. Studd, 2010, Climacteric : the journal of the International Menopause Society.

Scanning electron microscopic atlas of mammalian reproduction

P. Kenemans, 1976 .

Estrogenic uterovaginal effects of oral estetrol in the modified Allen–Doisy test

P. Kenemans, H. C. Coelingh Bennink, C. Holinka, 2008, Climacteric : the journal of the International Menopause Society.

Diagnostic applications to oncology

P. Kenemans, G. Hodges, 1982 .

Cell surface morphology in epithelial malignancy and its precursor lesions.

G. P. Vooys, P. Kenemans, J. Stolk, 1981, Scanning electron microscopy.

Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes

S. H. van der Burg, J. Drijfhout, W. Kast, 1993, European journal of immunology.

Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours.

C. Meijer, J. Walboomers, P. Stern, 1994, British Journal of Cancer.

Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

G. Fleuren, R. Offringa, W. Kast, 1997, The Journal of experimental medicine.

Experience with hormonal therapy in advanced epithelial ovarian cancer.

P. Kenemans, C. Burger, J. Vermorken, 1995, Acta oncologica.

Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening.

C. Meijer, J. Walboomers, P. Kenemans, 1992, IARC scientific publications.

Prognostic Factors in Borderline and Invasive Ovarian Tumours of the Common Epithelial Type

J. Baak, P. Kenemans, J. Stolk, 1987 .

Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides.

S. H. van der Burg, W. Kast, C. Melief, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Estrogens ,homocysteine ,vasodilatation and menopause: basic mechanisms ,interactions and clinical implications

P. Sipkema, P. Kenemans, M. J. Mooren, 2003, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Colposcopic findings and intraepithelial neoplasia in diethylstilbestrol-exposed offspring. The Dutch experience.

P. Kenemans, T. Helmerhorst, H. Stolk, 1989, American journal of obstetrics and gynecology.

The vagina (pathology)

G. P. Vooys, P. Kenemans, E. Hafez, 1982 .

Use of statistical evaluation of antigen profiles in differential diagnosis between colonic and ovarian adenocarcinomas.

P. Kenemans, S. Henzen‐Logmans, N. Schipper, 1988, Journal of clinical pathology.

Women's expectations and acceptance of cyclic induced HRT bleeds.

P. Kenemans, P. V. D. Weijer, P. V. D. van de Weijer, 1998, Maturitas.

Endometrial response in estrogen replacement therapy quarterly combined with a progestogen.

J. Baak, P. Kenemans, A. Haspels, 1996, Maturitas.

Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls

P. Kenemans, H. Nijman, A. Verstraeten, 1999, Cancer Immunology, Immunotherapy.

Immunohistochemical identification of Langerhans cells in normal epithelium and in epithelial lesions of the uterine cervix.

R. D. de Waal, P. Kenemans, F. Ramaekers, 1986, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women.

C. Schalkwijk, P. Kenemans, D. Braat, 2006, Human reproduction.

Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations.

P. Kenemans, A. Pines, V. Mijatovic, 1997, European journal of obstetrics, gynecology, and reproductive biology.

Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.

P. Kenemans, M. J. van der Mooren, R. Smolders, 2009, European journal of obstetrics, gynecology, and reproductive biology.

Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone.

P. Scholten, P. Kenemans, M. J. van der Mooren, 1999, Climacteric : the journal of the International Menopause Society.

Emerging Selective Estrogen Receptor Modulators

P. Kenemans, T. Vogelvang, V. Mijatovic, 2012, Drugs.

Hormone replacement and the menopause: a European position paper. Writing Group on Women's Health of the Fondazione Giovanni Lorenzini Medical Science Foundation.

P. Kenemans, R. Paoletti, M. Soma, 1997, European journal of obstetrics, gynecology, and reproductive biology.

Postmenopausal Hormone Therapy

P. Kenemans, Marius Jan Mooren, 2012, Drugs.

Postmenopausal hormone therapy and cancer risk

P. Kenemans, R. Verstraeten, R. Verheijen, 2005 .

Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue.

C. Meijer, P. Kenemans, C. Molthoff, 1995, Journal of clinical pathology.

Multicenter technical and clinical evaluation of a fully automated enzyme immunoassay for CA 125.

P. Kenemans, A. Keßler, G. V. van Kamp, 1992, Clinical chemistry.

MulticenterTechnicaland ClinicalEvaluationof a FullyAutomatedEnzyme Immunoassay for CA 125

P. Kenemans, G. Kamp, A. Verstraeten, 1992 .

Carcinoma‐associated mucin serum markers CA M26 and CA M29: Efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix

H. D. de Bruijn, T. Wobbes, P. Kenemans, 1991, International journal of cancer.

An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma.

R. Bast, V. Zurawski, R. Knapp, 1988, Gynecologic oncology.

Pre‐operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays

P. Kenemans, L. Massuger, L. Poels, 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

The influence of physiological and surgical menopause on coronary heart disease risk markers

P. Scheffer, P. Kenemans, R. Verheijen, 2009, Menopause.

An Enzyme-Linked Immunosorbent Assay for the Measurement of Circulating Antibodies to Polymorphic Epithelial Mucin (MUC1)

A. Kok, S. Meijer, M. Paul, 1998, Tumor Biology.

Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine.

M Nap, M R Suresh, R. Bast, 1996, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.

P. Kenemans, R. Verstraeten, G. V. van Kamp, 1996, American journal of obstetrics and gynecology.

Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays.

S. Meijer, P. Kenemans, R. Verstraeten, 1997, Clinical chemistry.

The Second Generation CA125 Assays

P. Kenemans, G. Kamp, A. Verstraeten, 1995 .

CA 125 and polymorphic epithelial mucin as serum tumor markers

R. Bast, M. Price, P. Kenemans, 1988 .

measured by ID-LC-MS/MS in postmenopausal women versus those in women who underwent bilateral oophorectomy

M. Blankenstein, P. Kenemans, L. Thienpont, 2010 .

Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer

P. V. van Diest, I. Jacobs, P. Shaw, 2002, Molecular pathology : MP.

Atlas of Human Reproduction: By Scanning Electron Microscopy

P. Kenemans, E. Hafez, 2012 .

Serum testosterone levels measured by isotope dilution-liquid chromatography–tandem mass spectrometry in postmenopausal women versus those in women who underwent bilateral oophorectomy

M. Blankenstein, P. Kenemans, L. Thienpont, 2010, Annals of clinical biochemistry.

Effect of Oral and Transdermal Estrogen Replacement Therapy on Hemostatic Variables Associated With Venous Thrombosis: A Randomized, Placebo-Controlled Study in Postmenopausal Women

C. Stehouwer, P. Kenemans, J. Rosing, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Diathermy loop excision in the management of cervical intraepithelial neoplasia: Diagnosis and treatment in one procedure

G. Vooijs, P. Kenemans, R. Rolland, 1992 .

Menopause, hormones and sex: the role of the doctor.

P. Kenemans, S. Palacios, 2009, Maturitas.

Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy

M. Beckmann, J. Foidart, P. Sismondi, 2012, Breast Cancer Research.

Tibolone revisited: still a good treatment option for healthy, early postmenopausal women

P. Kenemans, 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Tumour detection and localization using 99Tcm-labelled OV-TL 3 Fab' in patients suspected of ovarian cancer.

P. Kenemans, L. Massuger, S. Strijk, 1992, Nuclear medicine communications.

Kinetics and biodistribution in relation to tumour detection with 111 In labelled OV‐TL 3 F(ab,)2 in patients with ovarian cancer

P. Kenemans, R. Verheijen, L. Massuger, 1991, Nuclear medicine communications.

[The diagnostic value of immunoscintigraphy using the monoclonal antibody OV-TL3 in patients with ovarian carcinoma].

R. Golding, P. Kenemans, C. Burger, 1991, Nederlands tijdschrift voor geneeskunde.

Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody.

P. Kenemans, R. Verheijen, L. Massuger, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

CA 125: A valid marker in ovarian carcinoma patients treated with paclitaxel?

P. Kenemans, R. Verstraeten, W. W. ten Bokkel Huinink, 1996, Cancer.

Evaluation of an EIA kit for carcinoma-associated mucin antigens CA M26 and CA M29

A. Kok, P. Kenemans, G. Kamp, 1989 .

Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer.

A. Hart, G. Kenter, M. Gallee, 1994, Gynecologic oncology.

Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.

G. Kenter, P. Kenemans, K. Gaarenstroom, 1997, Anticancer research.

Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.

P. Kenemans, K. Gaarenstroom, B. V. van Bunningen, 1997, Anticancer research.

Postmenopausal hormone replacement therapy and cancer of the female genital tract and breast.

P. Kenemans, C. Burger, 1998, Current opinion in obstetrics & gynecology.

HPV genotype as a prognostic factor for progression to cervical carcinoma in young women.

P. Kenemans, 1994, European journal of obstetrics, gynecology, and reproductive biology.

HPV DNA presence and HPV genotypes as prognostic factors in low-stage squamous cell cervical cancer.

C. Meijer, J. Walboomers, M. Gallee, 1993, Gynecologic oncology.

Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study.

P. Kenemans, T. Teerlink, M. J. van der Mooren, 2007, Atherosclerosis.

The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass.

P. Kenemans, R. Verstraeten, R. Verheijen, 2002, American journal of obstetrics and gynecology.

P-71. Effects of Raloxifene on the Endometrium in Healthy Postmenopausal Women

P. Kenemans, B. Walsh, W. Scheele, 1997 .

Oral estradiol decreases plasma homocysteine, vitamin B6, and albumin in postmenopausal women but does not change the whole-body homocysteine remethylation and transmethylation flux.

P. Kenemans, K. de Meer, C. Jakobs, 2005, The Journal of clinical endocrinology and metabolism.

CA 125 half-life in ovarian cancer: a multivariate survival analysis.

L. Beex, P. Kenemans, J. Vermorken, 1993, British Journal of Cancer.

Tissue distribution of 99mTc, 111In and 123I-OV-TL 3 Fab' in ovarian carcinoma bearing nude mice.

P. Daddona, P. Kenemans, L. Massuger, 1991, International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology.

Nonspecific Uptake in Radioimmunoscintigraphy

P. Kenemans, L. Massuger, F. Corstens, 1990 .

The pathological placenta

H. Geijn, P. Kenemans, E. Hafez, 1982 .

Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life.

P. Kenemans, M. J. van der Mooren, 2004, Drugs.

Hormone replacement influences homocysteine levels in the methionine-loading test: a randomized placebo controlled trial in postmenopausal women.

P. Kenemans, K. de Meer, T. Teerlink, 2004, European journal of obstetrics, gynecology, and reproductive biology.

Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women.

P. Kenemans, J. C. Netelenbos, G. V. van Kamp, 1997, Journal of Clinical Endocrinology and Metabolism.

Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women.

C. Schalkwijk, P. Kenemans, T. Vogelvang, 2004, The American journal of cardiology.

Analysis of MHC Class I Expression in HPV 16 Positive Cervical Carcinomas, in Relation to C-MYC Overexpression

J. Walboomers, P. Kenemans, P. Snijders, 1994 .

MHC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression.

C. Meijer, J. Walboomers, P. Kenemans, 1993, Oncogene.

Expression of Cytokeratins in Early Neoplastic Epithelial Lesions of the Uterine Cervix

P. Kenemans, F. Ramaekers, G. Vooijs, 1985, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal women.

P. Kenemans, T. Teerlink, M. J. van der Mooren, 2007, Fertility and sterility.

Postmenopausal hormone therapy and breast cancer: what is the problem?

P. Kenemans, 2005, Maturitas.

High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy *E. H. Hopman Research Fellow, **L. Rozendaal Research Fellow, tF. J. Voorhorst Epidemiologist,

J. Walboomers, P. Kenemans, J. M. Helmerhorst, 2000 .

Erratum to “Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients—Design and baseline data ‘LIBERATE’ trial” [The Breast 16S2 (2007) S182–S189]

M. Beckmann, J. Foidart, P. Sismondi, 2008 .

Ovarian carcinogenesis, an alternative theory.

P. V. van Diest, P. Kenemans, R. Verheijen, 2007, Gynecologic oncology.

[The pill and cancer of the female sex organs and breast].

P. Kenemans, C. Burger, A. E. Bouwma, 1994, Nederlandsch tijdschrift voor geneeskunde.